RLAY compared with AMGN: revenue, margins and what each company keeps, and the suppliers and customers both name

RLAYRelay Therapeutics, Inc.

Mkt capRevenueRevenue

AMGNAmgen Inc

Mkt capRevenueRevenue

Compare

RLAYRelay Therapeutics, Inc.

AMGNAmgen Inc

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

RLAY

0 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±13.2%▼−5.71%×0.43

Q2 FY26±17.0%▲+0.10%×0.01

May 6 '26±14.2%▼−0.62%×0.04

Q1 FY26±40.7%▲+12.01%×0.29

AMGN

4 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±3.7%▲+3.73%×1.00

Q2 FY26±4.1%▲+4.57%×1.12

= impliedRLAY realized, solidAMGN realized, hatchedOne scale, both sides: full bar = 41%× = |realized| ÷ impliedSource: market data

Q1 FY26

±3.9%

▼−4.75%

×1.23

Feb 4 '26±3.7%▲+8.15%×2.22

RLAYRelay Therapeutics, Inc.

18.60▲+9.41%· post 18.60

Mkt cap$4.1BRevenue$350,000Q2 FY26Revenue—

AMGNAmgen Inc

460.55▲+0.06%· post 460.42

ClosedNov 6 '26

Mkt cap$249.0BRevenue$10.4BQ3 FY26Revenue$36.8BFY25

Compare

ClosedNov 6 '26

RLAYRelay Therapeutics, Inc.

AMGNAmgen Inc

18.60▲+9.41%post 18.60

Price

460.55▲+0.06%post 460.42

$4.1B

Mkt cap

$249.0B

Q2 FY26$350,000

Revenue

$10.4BQ3 FY26

—

Revenue

$36.8BFY25

RLAY18.60▲+9.41%vsAMGN460.55▲+0.06%ClosedNov 6 '26